FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01541 | 說明 H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | ...

Core Viewpoint - Yiming Anke-B (01541.HK) has successfully completed a placement agreement, raising approximately HKD 345.1 million for various research and operational purposes [1] Group 1: Placement Details - The placement involved the successful allocation of 24.2 million shares at a price of HKD 14.50 per share, representing about 5.94% of the company's issued share capital prior to the placement [1] - The shares allocated account for approximately 6.11% of the total issued H-shares before the placement and about 5.61% and 5.76% of the issued share capital and H-shares, respectively, after the placement [1] Group 2: Use of Proceeds - Approximately 40% of the net proceeds will be allocated to fund the research and development of IMM2510 and IMM27M for the treatment of solid tumors [1] - About 20% will be used for the development of IMM01 (Tideglusib) [1] - Approximately 10% will be directed towards the research of IMM0306 [1] - The remaining 30% will be utilized to supplement the company's working capital and for general corporate purposes [1]

Core Viewpoint - The company has successfully completed the placement agreement, with all conditions met and the delivery executed on October 16, 2025 [1] Summary by Relevant Sections - The placement agent has successfully allocated a total of 24.2 million shares at a price of HKD 14.50 per share to no fewer than six subscribers [1] - This allocation represents approximately 5.94% of the company's issued share capital prior to the delivery and about 6.11% of the total issued H shares [1] - Following the delivery and issuance of the placement shares, the allocated shares will account for approximately 5.61% of the company's enlarged issued share capital and about 5.76% of the total issued H shares [1]

Core Viewpoint - The company, Yiming Anke-B (01541), has successfully completed the placement agreement, with all conditions met and the delivery executed according to the terms on October 16, 2025 [1] Group 1: Placement Agreement Details - The placement agent has successfully placed a total of 24.2 million shares at a price of HKD 14.50 per share to no less than six subscribers [1] - This placement represents approximately 5.94% of the company's issued share capital immediately before the delivery and about 6.11% of the total issued H shares [1] - After the placement, the shares will account for approximately 5.61% of the company's issued share capital and about 5.76% of the total issued H shares [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 完成根據一般授權配售新H股 獨家整體協調人、配售代理及資本市場中介人 茲提述宜明昂科生物醫藥技術（上海）股份有限公司（「本公司」）日期為2025年10 月9日的公告，內容有關根據一般授權配售新H股（「配售公告」）。除非另有界 定，否則本公告所有詞彙與配售公告所界定者具相同涵義。 本公告僅供參考之用，並不構成收購、購買或認購本公司證券的邀請或要約。 本公告及其任何副本概不得直接或間接在美國，或在刊發或派發本公告屬違法的任何其他司 法權區刊發或派發。 本公告並非在美國購買或認購任何證券之要約或招攬，亦不構成其一部分。本公告所述證券 並未且不會根據《1933年美國證券法》（「美國證券法」）登記，亦不會在美國提呈或出售，除非 根據美國證券法作出登記或獲豁免或為毋須根據美國證券法作出登記之交易。本公司無意根 據美國證券法登記本公告內所指之任何證券，或在美國進行證券之公開發售。 ImmuneOnco Biopharm ...

Core Insights - The stock of Yiming Oncology-B (01541) rose over 5%, currently up 5.22% at HKD 11.47, with a trading volume of HKD 40.4765 million [1] Group 1: Nobel Prize Announcement - Three scientists, including Mary E. Blenko, were awarded the 2025 Nobel Prize in Physiology or Medicine for their research on peripheral immune tolerance mechanisms [1] - This innovative research identified the immune system's inhibitory switch, offering transformative therapies for millions suffering from autoimmune diseases and cancer [1] - Regulatory T cells (Treg cells) maintain immune tolerance through the Foxp3 transcription factor, with their dysfunction closely linked to autoimmune diseases and cancer [1] Group 2: Development of Tazlestobart - Yiming Oncology is actively advancing the clinical development of Tazlestobart (IMM27M), a next-generation CTLA-4 antibody [2] - Tazlestobart works by eliminating Treg cells in the tumor microenvironment to exert its anti-tumor effects [2] - The drug enhances ADCC activity through genetic engineering, targeting specific molecules on Treg cells to modulate their function or quantity, thereby boosting immune responses [2]

Core Viewpoint - The stock of Iminconco-B (01541) has risen over 5% due to increased attention on Treg cell therapy and the active clinical development of Tazlestobart monoclonal antibody [1][2] Group 1: Company Developments - Iminconco-B's stock price increased by 5.22%, reaching 11.47 HKD, with a trading volume of 40.47 million HKD [1] - The company is actively advancing the clinical development of Tazlestobart (IMM27M), a next-generation CTLA-4 antibody [2] Group 2: Scientific Recognition - Three scientists, including Mary E. Blenko, were awarded the 2025 Nobel Prize in Physiology or Medicine for their research on peripheral immune tolerance mechanisms, which has implications for autoimmune diseases and cancer therapies [1] - The discovery of regulatory T cells (Treg cells) and their mechanisms has provided a theoretical foundation for developing new immunomodulatory drugs [1] Group 3: Product Mechanism - Tazlestobart (IMM27M) is designed to eliminate Treg cells in the tumor microenvironment, enhancing anti-tumor efficacy [2] - The drug utilizes genetic engineering to enhance ADCC activity and targets specific molecules on Treg cells, particularly CTLA-4, to modulate their function or quantity [2]

Group 1 - Company Innovent Biologics (1541.HK) announced a placement of 24.2 million new H-shares, representing approximately 5.61% of the enlarged share capital, to raise HKD 351 million (USD 45 million) at a price of HKD 14.5 per share, which is a discount of about 12.97% from the previous closing price of HKD 16.66 [3] - The estimated net proceeds of approximately HKD 345 million will be used to fund the research and development of IMM2510 and IMM27M for the treatment of solid tumors, as well as for the development of IMM01 (Tislelizumab) and IMM0306, and to supplement working capital and general corporate purposes [3] - The company has submitted an application to the National Medical Products Administration for a Phase III clinical trial of IMM2510 for the treatment of immune-resistant non-small cell lung cancer (NSCLC) [3] Group 2 - The company's stock opened lower on Thursday, trading at HKD 14.46 at noon, down 13.21%. However, the stock has increased by 180% year-to-date [3]

Core Viewpoint - The company plans to issue a total of 24.2 million new H-shares at a price of HKD 14.50 per share, representing a discount of approximately 12.97% from the closing price of HKD 16.66 on October 8, 2025 [1] Fundraising Details - The total estimated gross proceeds from the placement are approximately HKD 350.9 million, with net proceeds estimated at around HKD 345 million [1] - The net proceeds will be allocated as follows: - Approximately 40% for funding the research and development of IMM2510 and IMM27M for the treatment of solid tumors - Approximately 20% for funding the research and development of IMM01 (Tideglusib) - Approximately 10% for funding the research and development of IMM0306 - Approximately 30% for supplementing the company's working capital and general corporate purposes [1]

Core Viewpoint - The company plans to issue a total of 24.2 million new H-shares at a price of HKD 14.50 per share, representing a discount of approximately 12.97% from the closing price of HKD 16.66 on October 8, 2025 [1] Fundraising Details - The total estimated gross proceeds from the placement are approximately HKD 350.9 million, with net proceeds estimated at around HKD 345 million [1] - The net proceeds will be allocated as follows: - Approximately 40% for funding the research and development of IMM2510 and IMM27M for the treatment of solid tumors - Approximately 20% for funding the research and development of IMM01 (Tideglusib) - Approximately 10% for funding the research and development of IMM0306 - Approximately 30% for supplementing the company's working capital and general corporate purposes [1]